pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 24·1 min read
save

Rigel Pharmaceuticals appoints Alison Hannah as executive vice president and chief medical officer

Jul 24, 2026·read at STAT ↗Positive

Rigel Pharmaceuticals announced that it has hired Alison Hannah to serve as executive vice president and chief medical officer.

Hannah joins Rigel after holding the same senior medical leadership role at CytomX Therapeutics, where she oversaw clinical development and medical affairs.

The appointment adds a seasoned executive to Rigel’s leadership team as the company continues to advance its pipeline and strategic initiatives.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Up and down the ladder: The latest comings and goings”

read at STAT ↗
459 words · retrieved Jul 24
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
RIGEL PHARMACEUTICALS INC2CytomX Therapeutics, Inc.LILLYRISING
drugs
Obesity
topics
Obesity

related stories

  • Aug 5STAT+: Once again, child dies in gene-editing trial in China, rekindling debate on transparency and safetySTAT
  • Aug 5STAT+: Exemption of rare disease therapies in drug-pricing pilots would wipe out huge savings, analysis findsSTAT
  • Aug 4Novo dips 6% on Wegovy pill stumble despite Q2 earnings beatBioSpace
  • Jul 27Apnimed aspires for up to $160M IPO as sleep apnea pill launch nearsFierce Biotech
  • Jul 24STAT+: Merck strikes voluntary licensing deals in poor countries for an experimental HIV prevention pillSTAT